The aim of this study is to determine if cats with chronic rhinitis (FCR) will respond to intranasal steroid treatment. There is no current standard of care treatment for this disease, and it can be associated with significant morbidity, greatly impacting the cat’s quality of life. Cat owners will be asked to fill out a survey (SNIFLD-C questionnaire) to determine how severe their cat’s disease is at enrollment, during treatment, and after treatment for 4 weeks. Based on their SNIFLD-C scores, we hope to determine if treatment with an intranasal steroid drop (fluticasone or prednisolone) is better than treatment with a placebo (saline). Cats diagnosed with biopsy-confirmed lymphoplasmacytic rhinitis (LPR), which is a form of FCR, will be eligible for enrollment. They will be randomly assigned to receive placebo (saline) or fluticasone drops. If a cat does not respond to treatment (either placebo or fluticasone) after 2 weeks, they can be automatically enrolled in a second-tier treatment option (fluticasone for saline cats, and prednisolone for fluticasone cats). We are hopeful that this study can provide evidence-based treatment options for cats with this condition.